Lonza Lunchtime Networking Event

OBN are pleased to be delivering a special lunchtime learning & networking event with the team at Lonza Biologics. The lunchtime session will include presentations from Lonza's Early Development Services, which covers late discovery up to lead candidate optimization and stability testing and their Drug Product Services, which includes the latest steps of drug manufacturing for clinical and commercial purposes.

Presentations will be followed by a networking lunch at the Beehouse on Milton Park, where you'll have the chance to meet industry colleagues alongside the Lonza team, followed by the chance to book a follow-up 1-1 partnering meeting.

Outline Programme:

11.30  Guest arrival and networking

11.45  Keynote presentations from the Lonza Team:

  • Daniel Kullmann, Associate Principal Scientist Drug Product Services, 'A toolbox for formulatability screening of mAbs and novel modalities
  • Raymond Donninger, Senior Director Commercial Development, Early Development Services, 'De-Risking and Optimizing Your Early Development Pathway'

12.25  Audience Q&A

12.35  Networking Lunch

13.30  Depart or optional 1-1 Partnering meetings with the Lonza team

Who should attend:

This event is complimentary and available on an 'apply to attend' basis for biotech and pharma companies of all sizes who are involved in or interested in the development of innovative biologics therapies.

Further Information

Keynote presentation one: A Toolbox for formulatability screening of mAbs and novel modalities

The early identification of liabilities and CMC risks for mAb and simple bispecifics can ease the development of these molecule types and allows the flagging of challenges, for both the manufacturing and the long-term storage of the molecule-of-interest. For diverse novel modalities of greater complexity, a comprehensive understanding of the physicochemical characteristics and liabilities is often lacking in the early development, posing a risk to a successful and timely development. Our strategies can overcome these risks by rapidly evaluating several candidates with minute amounts of material and clearing the first steps in the path to IND by utilizing e.g. comprehensive solution condition screening, high throughput candidate ranking and automated data visualization workflows.

Keynote presentation two: De-risking and Optimizing Your Early Development Pathway

We live in a time characterized by rapid deadlines, highly dynamic changes and the rise of complex molecular structures. Strategies are ever evolving and are necessary to guarantee the commercial success of therapeutic advancements. Our expertise in the early development of biologics therapeutics and drug product services, allow us to investigate and apply key strategies for overcoming challenges and streamlining processes in early-stage drug development.

About Lonza Biologics

A fully integrated CDMO that offers innovative development and manufacturing services and technologies from late phase drug discovery to market supply, from drug substance to drug product across a variety of molecule types. Click here for more details.